CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial

CG Oncology, Inc.

CG Oncology, Inc.

CGON

0.00

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively

- High-Grade - EFS in the overall intention-to-treat population was 96.0% at 3 months and 89.5% at 6 months

- Efficacy was comparable across concurrent and sequential treatment arms and across both BCG-exposed and BCG-Unresponsive populations

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.